Aeruginascin: The Mushroom Compound Linked to Euphoria

Psychedelic Chemistry

226 Samples

A 2022 analysis of 226 psychotropic mushroom fruiting bodies from 82 collections measured aeruginascin alongside psilocybin, psilocin, baeocystin, and norbaeocystin. Tryptamine concentrations varied enormously across species and even within species.

Gotvaldova et al., IJMS, 2022

5 Tryptamines

now measurable in mushroom tissue

1989

first link to euphoric experiences

No Head Twitch

in mouse models at tested doses

Gotvaldova et al., IJMS, 2022

View as image ↗

Aeruginascin is a naturally occurring tryptamine alkaloid found in certain psilocybin-containing mushroom species. Its chemical name is N,N,N-trimethyl-4-phosphoryloxytryptamine. It differs from psilocybin by a single methyl group: where psilocybin has two methyl groups on its nitrogen (a tertiary amine), aeruginascin has three (a quaternary ammonium compound). That structural difference may change how the compound interacts with serotonin receptors, crosses the blood-brain barrier, and contributes to the overall experience produced by mushrooms that contain it. For a broader overview of the full chemical profile of psychedelic mushrooms, that article covers all the tryptamines. The question of whether minor tryptamines produce an entourage effect gets its own analysis.

Discovery and Structure

Aeruginascin was first described as a distinct compound in Inocybe aeruginascens, a psilocybin-containing mushroom species. Jensen, Gartz, and Laatsch published its structural identification in Planta Medica in 2006.^[1] They determined it to be the quaternary ammonium compound N,N,N-trimethyl-4-phosphoryloxytryptamine. The paper noted that aeruginascin is structurally related to bufotenidine (5-HTQ), a frog skin toxin and potent 5-HT3 receptor agonist.

The structural relationship to psilocybin is direct. Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a tertiary amine with two methyl groups on its nitrogen. Aeruginascin adds a third methyl group, creating a permanent positive charge. This charge has pharmacological consequences: quaternary ammonium compounds generally cross the blood-brain barrier less efficiently than their tertiary counterparts. Whether aeruginascin itself reaches the brain at meaningful concentrations, or acts through a dephosphorylated metabolite (4-hydroxy-N,N,N-trimethyltryptamine, or 4-HO-TMT), remains an open question.

The Euphoria Connection: What the Evidence Actually Shows

The claim that aeruginascin makes mushroom experiences "friendlier" traces to a single data source. In 1989, Jochen Gartz analyzed 23 cases of accidental Inocybe aeruginascens intoxication. All 23 cases involved exclusively euphoric experiences. This contrasted with reports from accidental ingestion of other psilocybin mushrooms (containing only psilocybin and psilocin), where some individuals reported dysphoric or anxious reactions.

Gartz hypothesized that aeruginascin modified the psychedelic effect of the co-occurring tryptamines, producing an overall euphoric feeling. This hypothesis has been widely cited in popular discussion of the "mushroom entourage effect." Several limitations apply: the sample was small (23 cases), the reports were retrospective, no plasma concentrations were measured, and the species identification was the primary variable (different species contain different ratios of all tryptamines, not just different aeruginascin levels). The euphoria could have been caused by aeruginascin, by the overall tryptamine ratio in Inocybe aeruginascens, by the lower total psilocybin content in that species, or by factors unrelated to chemistry.

Pharmacology: What Happens at Serotonin Receptors

Two major pharmacological studies have addressed aeruginascin and related tryptamines directly.

Sherwood and colleagues published a synthesis and biological evaluation of norbaeocystin, baeocystin, norpsilocin, and aeruginascin in the Journal of Natural Products in 2020.^[2] Their key findings: baeocystin did not produce psychedelic-like activity in the mouse head twitch response assay, despite the fact that its putative dephosphorylated metabolite norpsilocin showed potent 5-HT2A agonist activity in vitro. This means the phosphorylated form (the one that exists in the mushroom) did not produce the behavioral proxy for a psychedelic experience, even though its broken-down form binds the relevant receptor. The implication is that metabolism and pharmacokinetics, not just receptor binding, determine whether a compound produces a psychedelic effect.

Glatfelter and colleagues expanded this work in a 2022 study published in ACS Pharmacology and Translational Science.^[3] They tested psilocybin, baeocystin, aeruginascin, and their 4-acetoxy and 4-hydroxy analogues using radioligand binding assays in transfected cells, calcium mobilization assays, beta-arrestin 2 recruitment assays, and in vivo mouse experiments. The results were clear on one point: only the tertiary amines (psilocybin, psilocin, and psilacetin) induced head twitch responses (ED50 0.11-0.29 mg/kg) indicative of psychedelic-like activity. Head twitches were blocked by 5-HT2A antagonist pretreatment, confirming serotonin 2A involvement.

Baeocystin and aeruginascin did not produce head twitch responses at tested doses. Both secondary and tertiary amines decreased body temperature and locomotor activity at higher doses, effects that were blocked by 5-HT1A antagonist pretreatment. This means the minor tryptamines may have non-psychedelic serotonergic activity (through 5-HT1A) without producing the hallmark psychedelic response (through 5-HT2A).

The aeruginascin metabolite 4-HO-TMT has been separately synthesized and tested. Competitive radioligand binding assays show it binds at human 5-HT1A, 5-HT2A, and 5-HT2B receptors with inhibition constants of 4,400, 670, and 120 nM respectively. These affinities are weaker than psilocin's at 5-HT2A but the 5-HT2B affinity is notable. Whether 4-HO-TMT forms from aeruginascin in vivo and reaches serotonin receptors at functionally relevant concentrations has not been established.

How Much Aeruginascin Is in Mushrooms?

Gotvaldova and colleagues answered this question with the largest alkaloid profiling study to date, published in the International Journal of Molecular Sciences in 2022.^[4] They measured psilocybin, psilocin, baeocystin, norbaeocystin, and aeruginascin in 226 fruiting bodies from 82 individual collections across seven mushroom genera, using ultra-high performance liquid chromatography coupled with tandem mass spectrometry. For many species, aeruginascin concentrations were reported for the first time.

The findings confirm what earlier, smaller studies suggested: tryptamine concentrations are extremely variable. Different species contain different tryptamine profiles. Psilocybe species had the highest psilocybin and psilocin concentrations overall, but no tryptamines were detected in P. fuscofulva and P. fimetaria collections. The paper explicitly noted that "the varied cocktail of tryptamines in wild mushrooms could influence the medicinal effect compared to therapy with chemically pure PSB." The corollary of understanding what baeocystin and norbaeocystin do fills in the rest of the tryptamine picture. The question of whether these minor compounds change the experience is explored separately.

A separate stability study by Gotvaldova and colleagues (2021) measured the stability of psilocybin and four of its analogues in dried Psilocybe cubensis biomass.^[5] They found that degradation rates differ by compound, meaning the tryptamine ratio in a mushroom changes over time after harvest. This has direct implications for entourage effect claims: the ratio of tryptamines a person ingests depends not only on the species but on how the mushroom was stored and how long ago it was dried.

What Aeruginascin Does Not Tell Us

The current evidence has several gaps:

No human pharmacological studies exist for aeruginascin or 4-HO-TMT. All receptor binding and behavioral data come from in vitro assays and mouse models. The head twitch response is a well-validated behavioral proxy for psychedelic activity in mice, but mice are not humans.

The euphoria claim rests on 23 retrospective reports from a single species. Those reports did not control for dose, set, setting, individual variation, or the overall tryptamine profile of the mushrooms consumed. Attributing the euphoria specifically to aeruginascin rather than the full chemical cocktail of Inocybe aeruginascens is a hypothesis, not a conclusion.

Blood-brain barrier penetration is unknown. As a quaternary ammonium compound, aeruginascin carries a permanent positive charge that typically limits CNS penetration. Whether it crosses at relevant concentrations, and whether its metabolite 4-HO-TMT forms and accumulates in the brain, are unanswered questions.

The entourage effect remains unproven. The concept is borrowed from cannabis pharmacology. In the mushroom context, no controlled study has compared the subjective effects of pure psilocybin against a matched dose of psilocybin combined with aeruginascin, baeocystin, or other minor tryptamines in humans.

The Bottom Line

Aeruginascin is a real compound with a defined structure: the trimethylated, quaternary ammonium analogue of psilocybin. It was first found in Inocybe aeruginascens, and 23 accidental intoxications with that species produced exclusively euphoric reports. Pharmacological studies show that aeruginascin and baeocystin do not produce psychedelic-like head twitch responses in mice at tested doses, though they may have non-psychedelic serotonergic effects through 5-HT1A. The largest alkaloid survey to date confirms that aeruginascin occurs in multiple mushroom species at variable concentrations. Whether it contributes to a "friendlier" experience in humans requires controlled studies that do not yet exist.

Frequently Asked Questions

What is aeruginascin in mushrooms?

Aeruginascin is a naturally occurring tryptamine alkaloid found in certain psilocybin-containing mushroom species. Its chemical name is N,N,N-trimethyl-4-phosphoryloxytryptamine. It differs from psilocybin by one extra methyl group on the nitrogen, making it a quaternary ammonium compound. Jensen, Gartz, and Laatsch identified its structure in Planta Medica in 2006 from the mushroom Inocybe aeruginascens. It has since been detected in multiple Psilocybe species.

Does aeruginascin make mushrooms feel different?

A 1989 analysis of 23 accidental Inocybe aeruginascens intoxications reported only euphoric experiences, unlike the mixed reactions from other psilocybin species. This observation has been widely cited as evidence that aeruginascin modulates the psychedelic experience. Pharmacological studies in mice show that aeruginascin does not produce head twitch responses (the behavioral proxy for psychedelic activity) at tested doses (Glatfelter et al., 2022). No controlled human studies comparing experiences with and without aeruginascin exist.

Is aeruginascin psychedelic?

In mouse models, aeruginascin did not produce the head twitch response associated with psychedelic activity at doses tested. Only tertiary amines like psilocybin, psilocin, and psilacetin produced this response (Glatfelter et al., ACS Pharmacology, 2022). Aeruginascin may have non-psychedelic serotonergic effects through 5-HT1A receptor activity, including reductions in body temperature and locomotor activity. Its metabolite 4-HO-TMT binds serotonin receptors in vitro but with lower affinity than psilocin at 5-HT2A.

What is the entourage effect in magic mushrooms?

The mushroom entourage effect is the hypothesis that minor tryptamines (baeocystin, norbaeocystin, aeruginascin) work together with psilocybin to produce effects different from pure psilocybin alone. Gotvaldova et al. (2022) confirmed that wild mushrooms contain a "varied cocktail of tryptamines" that could influence effects. No controlled human study has directly tested this hypothesis by comparing pure psilocybin to a multi-tryptamine mushroom preparation at matched psilocybin doses.

Which mushrooms contain aeruginascin?

Aeruginascin was first identified in Inocybe aeruginascens (Jensen et al., 2006). Gotvaldova et al. (2022) detected it across multiple genera in their survey of 226 fruiting bodies from 82 collections. Concentrations vary enormously between and within species. The compound has been confirmed in several Psilocybe species, though not all psilocybin-containing mushrooms produce aeruginascin. Each species has its own distinct tryptamine alkaloid profile.

How does aeruginascin differ from psilocybin chemically?

Psilocybin is 4-phosphoryloxy-N,N-dimethyltryptamine, a tertiary amine with two methyl groups on its nitrogen. Aeruginascin is 4-phosphoryloxy-N,N,N-trimethyltryptamine, a quaternary ammonium compound with three methyl groups. This extra methyl group creates a permanent positive charge, which typically reduces the ability to cross the blood-brain barrier. Structure-activity relationship studies show that this change eliminates the psychedelic-like head twitch response in mice while preserving some serotonergic activity through other receptor subtypes (Glatfelter et al., 2022).

Sources & References

1. 1RTHM-00101·Jensen, Niels et al. (2006). “Aeruginascin, a trimethylammonium analogue of psilocybin from the hallucinogenic mushroom Inocybe aeruginascens..” Planta medica.Study breakdown →PubMed →↩
2. 2RTHM-00654·Sherwood, Alexander M et al. (2020). “Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin..” Journal of natural products.Study breakdown →PubMed →↩
3. 3RTHM-00759·Glatfelter, Grant C et al. (2022). “Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice..” ACS pharmacology & translational science.Study breakdown →PubMed →↩
4. 4RTHM-00762·Gotvaldová, Klára et al. (2022). “Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids..” International journal of molecular sciences.Study breakdown →PubMed →↩
5. 5RTHM-00688·Gotvaldová, Klára et al. (2021). “Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis..” Drug testing and analysis.Study breakdown →PubMed →↩